by Peter Ciszewski | Apr 5, 2018
Rob Neville of Savara Pharmaceuticals discusses Pulmonary Alveolar Proteinosis (PAP) is a rare lung disease, which affects approximately 7 persons in a million people. It is characterised by the build-up of grainy material in the air sacs (alveoli) in the lungs. The...
by Peter Ciszewski | Apr 4, 2018
There continues to be a lot of activity and hope for patients suffering from , a rare and progressive fatal disease associated with restrictive cardiomyopathy and progressive heart failure. Although there are currently no approved therapies specifically indicated for...
by Peter Ciszewski | Apr 3, 2018
Stefan Weber, CEO of Newron Pharmaceuticals discusses how his company works with Rett Syndrome advocacy groups. Newron is focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. Xadago (safinamide) has...
by Peter Ciszewski | Apr 2, 2018
Chris Garabedian Discusses Interacting With Duchenne muscular dystryphy Patients and...
by Peter Ciszewski | Apr 1, 2018
Jan-Anders Karlsson discusses Verona Pharma’s lead candidate, RPL554, as a potential therapy for cystic fibrosis (CF) patients. Verona Pharma is currently undertaking a comprehensive Phase 2 clinical trial programme for nebulized RPL554 as a maintenance...
